Long‐term efficacy and safety of programmed death‐1 (PD‐1) antibody alone in relapsed/refractory human immunodeficiency virus‐associated Hodgkin lymphoma

We report a young patient initially diagnosed with human immunodeficiency virus (HIV)‐associated Hodgkin lymphoma (HL), and received six cycles of ABVD chemotherapy regimens and involvement field irradiation therapy. However, the disease progressed after two months later, and then received second li...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chaoyu, Zhou, Fanlin, Zhang, Lingqian, Liu, Tingting, Nan, Yingyu, Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421984/
https://www.ncbi.nlm.nih.gov/pubmed/36051083
http://dx.doi.org/10.1002/jha2.448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421984/
https://www.ncbi.nlm.nih.gov/pubmed/36051083
http://dx.doi.org/10.1002/jha2.448

Ejemplares similares